Publications by authors named "P P Swoboda"
Myocardial ischaemia following COVID-19: a cardiovascular magnetic resonance study.
Int J Cardiovasc Imaging
December 2024
The pathophysiology of myocardial injury following COVID-19 remains uncertain. COVID-HEART was a prospective, multicentre study utilising cardiovascular magnetic resonance (CMR) to characterise COVID-related myocardial injury. In this pre-specified analysis, the objectives were to examine (1) the frequency of myocardial ischaemia following COVID-19, and (2) the association between ischaemia and myocardial injury.
View Article and Find Full Text PDFMetformin is an antihyperglycemic used to treat type 2 diabetes mellitus (T2DM). Patients with T2DM are at increased risk of cardiovascular disease. We explored the association between metformin use and cardiovascular magnetic resonance (CMR) derived stress myocardial blood flow (MBF), myocardial perfusion reserve (MPR) and major adverse cardiovascular events (MACE; all cause death, MI, stroke, heart failure hospitalisation and coronary revascularisation) in patients with T2DM.
View Article and Find Full Text PDF(1) : Flow assessment using cardiovascular magnetic resonance (CMR) provides important implications in determining physiologic parameters and clinically important markers. However, post-processing of CMR images remains labor- and time-intensive. This study aims to assess the validity and repeatability of fully automated segmentation of phase contrast velocity-encoded aortic root plane.
View Article and Find Full Text PDFArticle Synopsis
- * The study will recruit approximately 1955 participants for home-based ECG monitoring, and will conduct comprehensive assessments, including physical exams and advanced imaging techniques.
- * The research aims to identify how other health issues affect AF development, find prevention strategies, and establish a foundation for future clinical trials on AF detection and prevention.
Article Synopsis
- The study examined the effects of myocardial injury in hospitalized COVID-19 survivors who had elevated troponin levels, using cardiac imaging and tracking health-related quality of life over 12 months.* -
- Conducted in 25 UK centers, the research involved 342 participants, finding that while some cardiovascular events occurred, overall major adverse outcomes were low after 12 months.* -
- Results showed slight improvements in heart function and quality of life after 6 months, with no evidence of ongoing myocardial inflammation or progression of heart injury.*